Acceleron Pharma Inc. (XLRN): Is it a better investment

0
60

Acceleron Pharma Inc. (NASDAQ:XLRN) changes shares on Monday trading session, with a change of 3.37% or $3.42 shares. The trading starts at $101.56 and closed at $101.38 throughout the day. The trading session low price was $99.74 and day high was $106.95 on Monday, June 22. After the session, the Healthcare sector daily volume shifted to 0.83 million while its average volume is 454.94K. In other hand, the XLRN market cap reached to $5.53B. While, its current target price is $104.80 according to WSJ.

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 10.19% and up 5.76% for month. Its quarterly performance was 47.98% above, while its half year performance is up 96.48%. XLRN yearly performance stood at positive 160.83% and rise 97.66% for year-to-date. Current recommendation for Acceleron Pharma Inc. is 2.00.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. XLRN EPS (TTM) for 12-month is -2.60. EPS for this year is 8.10%, while for the next year its value is -2.81. Its EPS Q/Q reached -28.30%. It has an EPS of -7.90% down for past five years.

Let’s take a look on the analyst recommendations on XLRN for the current month and previous month. For the current month, 10 of 12 analysts recommend stock as Buy while 1 as Sell, 0 as overweight, 0 as underweight and 1 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $72.00-$137.00. Average target price for XLRN was reached at $117.58.

FMR, LLC, Blackrock Inc. and Vanguard Group, Inc. (The) are the top three holders in Acceleron Pharma Inc. (XLRN) stock. On Mar 30, 2020, FMR, LLC has 8.0 million shares which valued 718.97 million. On Mar 30, 2020, Blackrock Inc. owned 5.12 million shares which valued at 460.07 million. On Mar 30, 2020, Vanguard Group, Inc. (The) has a total of 4.26 million shares which valued at 382.95 million. In the end, Vanguard Group, Inc. (The) have 7.92% shares outstanding of Acceleron Pharma Inc. (XLRN) on Mar 30, 2020. The insider ownership moved to 0.50% and institutional holding shifted to 90.50%.

The company posted an EPS (TTM) of -2.60. According to the most recent quarter report on (Jun 2020), 12 analysts estimated an average EPS of -0.66, while -0.34 EPS posted a year ago period. Analyst Estimated EPS for XLRN published in the report was -1.06-0.13 during the same period. Comparing with last year, the average estimated EPS was -0.34 which is higher than -0.95 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for XLRN rise 50.94% for period of 200 days. SMA for 50 days was 7.85% which is showing green signal, while SMA-20 was 8.84%. The moving average value for Acceleron Pharma Inc. (XLRN) is 82.09 and 98.42 for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in XLRN stock. On Apr 09, MCLAUGHLIN KEVIN F, SVP, CFO and Treasurer, sold 17,226 trading shares at the cost of $88.19, which valued at 1.52 million. On Apr 08, MCLAUGHLIN KEVIN F, SVP, CFO and Treasurer, sold 36,774 shares at the cost of $85.51, with total shares of 11,216. On Apr 08, Veness Adam M, SVP, General Counsel and Sec., sold 6,000 shares at the cost of 85.58. After this transaction, Veness Adam M total shares reached to 21,161 which valued at 0.51 million.